Cover Image
Market Research Report

Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities

Published by GBI Research Product code 246717
Published Content info 64 Pages
Immediate Delivery Available
Price
Back to Top
Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities
Published: July 10, 2012 Content info: 64 Pages
Description

Summary

GBI Research, leading business intelligence provider, has released its latest research report, entitled "Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities". It provides a comprehensive overview of the healthcare system, and the pricing and reimbursement processes in the top seven countries of the world, with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes the major pharmaceutical changes and oncology-related pricing and reimbursement in these countries in the recent past and their impact in the near future. The countries analyzed in the report are the US, the top five European countries of the UK, France, Italy, Germany and Spain; and Japan.

Cancer is considered to be one of the most feared diseases, a cure for which has so far eluded researchers all over the world. However, new lines of therapeutics Vascular Endothelial Growth Factor (VEGF) inhibitors and Epidermal Growth Factor Receptor (EGFR) inhibitors are expected to make a significant impact on patient survival. However, progress in patient survival and other benefits are accompanied by premium prices, which has necessitated the creation of several agencies responsible for making decisions pertaining to pricing and reimbursement for cancer drugs in many countries of the world in order to contain costs related to cancer treatment. The report on "Pharmaceutical Pricing and Reimbursement in Oncology " delves into these recent changes in pricing and reimbursement mechanisms that are often targeted at expensive cancer drugs.

Scope

  • Detailed study of the healthcare systems and roles of the key players in the respective pharmaceutical systems of the top seven countries of the world - the US, the UK, France, Germany, Italy, Spain and Japan.
  • Analysis of the major pricing and reimbursement mechanisms in each country.
  • Key trends that follow from the recent changes brought about in pricing and reimbursement mechanisms.
  • Analysis of the possible major challenges brought about by the enactment of changes in the pricing and reimbursement scene in the countries covered in the report.
  • Particular focus on pricing and reimbursement in oncology.

Reasons to buy

  • Build an understanding of the oncology-related key pricing and reimbursement mechanisms in the top seven countries of the world.
  • Optimize your investment through identification and understanding of the changes in oncology drugs' regulatory mechanisms and in the pricing and reimbursement scenario for the countries covered in the report.
  • Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene for the countries covered.
Table of Contents
Product Code: GBIHC203MR

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Pricing and Reimbursement in Oncology. Introduction

3. Pricing and Reimbursement in Oncology. Overview

  • 3.1. Development of Oncology Drugs
  • 3.2. Market Access and the Role of Health Economics in Cancer Drugs
    • 3.2.1. Regulation of Cancer Drugs in Europe
    • 3.2.2. Hospital Budgets and Patient Access to Drugs
    • 3.2.3. Payers Managing Influx of New Therapies through Innovative Strategies
    • 3.2.4. Risk Sharing Agreements in the US Vis-a-vis Europe
  • 3.3. Difference in Reimbursement for Oncology Drugs between the US and Europe
  • 3.4. Rationalizing Costs in the US

4. Pricing and Reimbursement in Oncology. The US

  • 4.1. Introduction
  • 4.2. Regulatory Bodies
  • 4.3. Trends
    • 4.3.1. Oncology Practice and Expenditure in the US
    • 4.3.2. Expenditure on Cancer Care Until 2020-Costs May Increase by 27% from 2010
    • 4.3.3. Reimbursement of Prescription Drugs. Oncology Falls under Tier Four
    • 4.3.4. Strategies to Control Healthcare Spending
    • 4.3.5. Oral Targeted Chemotherapeutics are the Next Paradigm in Cancer Care
    • 4.3.6. Reimbursement Issues in Oral Chemotherapeutics
    • 4.3.7. Oral Chemotherapy Parity Act

5. Pricing and Reimbursement in Oncology. Top Five Countries of Europe

  • 5.1. Italy
    • 5.1.1. Introduction
    • 5.1.2. Regulatory Bodies
    • 5.1.3. Trends
  • 5.2. Spain
    • 5.2.1. Introduction
    • 5.2.2. Regulatory Bodies
    • 5.2.3. Trends
  • 5.3. Germany
    • 5.3.1. Introduction
    • 5.3.2. Regulatory Bodies
    • 5.3.3. Trends
  • 5.4. France
    • 5.4.1. Introduction
    • 5.4.2. Regulatory Bodies
    • 5.4.3. Trends
  • 5.5. The UK
    • 5.5.1. Introduction
    • 5.5.2. Regulatory Bodies
    • 5.5.3. Trends

6. Pricing and Reimbursement in Oncology. Japan

  • 6.1. Introduction
  • 6.2. Regulatory Bodies
  • 6.3. Trends
    • 6.3.1. Fee Changes for the Elderly in Japan Suffering from Cancer
    • 6.3.2. Off-label Uses of Drugs Agreed to be Given Conditional Reimbursement
    • 6.3.3. Changes to Japan's Pricing System for Market Leading Drugs
    • 6.3.4. New Medicines Included in NHI List Including Eisai's Breast Cancer Drug Halaven

7. Pricing and Reimbursement in Oncology. Appendix

  • 7.1. Market Definitions
  • 7.2. Abbreviations
  • 7.3. Sources
  • 7.4. Research Methodology
    • 7.4.1. Introduction
    • 7.4.2. Regulatory Bodies
    • 7.4.3. Key Trends
  • 7.5. Contact Us
  • 7.6. Disclaimer

List of Tables

  • Table 1: Pricing and Reimbursement in Oncology, Estimated Number of New Cases for Major Types of Cancer, Top Seven Countries ('000), 2011
  • Table 2: Pricing and Reimbursement in Oncology, Estimated Mortality for Major Types of Cancer, Top Seven Countries ('000), 2011
  • Table 3: Pricing and Reimbursement in Oncology, Examples of Innovative Reimbursement Agreements
  • Table 4: Pricing and Reimbursement in Oncology, the US, Expenditure for Cancer Care in the Top Five Sites ($bn), 2010 and 2020
  • Table 5: Pricing and Reimbursement in Oncology, the US, Expenditure for Cancer Care in Other Sites ($bn), 2010 and 2020
  • Table 6: Pricing and Reimbursement in Oncology, Average Retail Coinsurance Rates, the US, By Tier (%), 2011
  • Table 7: Pricing and Reimbursement in Oncology, Public Pharmaceutical Expenditure, Pharmacies, 2010-2012
  • Table 8: Pricing and Reimbursement in Oncology, Germany, Healthcare Expenditure by Financing Agent, $ per inhabitant, 2007, 2008, 2009
  • Table 9: Pricing and Reimbursement in Oncology, France, Types of Treatment and their Reimbursement Levels
  • Table 10: Pricing and Reimbursement in Oncology, Market Entry Restrictions for Cancer Drugs, the UK
  • Table 11: Pricing and Reimbursement in Oncology, the UK, General Price Changes (%), 2009-2013
  • Table 12: Pricing and Reimbursement in Oncology, Healthcare Expenditure, Japan, 2011
  • Table 13: Pricing and Reimbursement in Oncology, Trend in Revision Rates of Reimbursement Prices, Japan, 1992-2008
  • Table 14: Pricing and Reimbursement in Oncology, Change in Premiums, Japan, 2002-2008
  • Table 15: Pricing and Reimbursement in Oncology, List of Drugs Introduced to NHI, Japan, 2011

List of Figures

  • Figure 1: Pricing and Reimbursement in Oncology, Estimated Number of New Cases or Major Types of Cancer, Top Seven Countries, ('000), 2015
  • Figure 2: Pricing and Reimbursement in Oncology, Estimated Number of New Cases for Major Types of Cancer, Top Seven Countries ('000), 2011
  • Figure 3: Pricing and Reimbursement in Oncology, Estimated Mortality for Major Types of Cancer, Top Seven Countries ('000), 2011
  • Figure 4: Pricing and Reimbursement in Oncology, the US, Total Healthcare Expenditure vs. Out-of-Pocket Expenditure (%), 2011
  • Figure 5: Pricing and Reimbursement in Oncology, the US, Expenditure for Cancer Care ($bn), 2010 and 2020
  • Figure 6: Pricing and Reimbursement in Oncology, the US, Expenditure for Cancer Care in the Top Five Indications ($bn), 2010 and 2020
  • Figure 7: Pricing and Reimbursement in Oncology, the US, Estimated Cancer Cases, By Sites, Men (%), 2011
  • Figure 8: Pricing and Reimbursement in Oncology, the US, Estimated Cancer Cases, By Sites, Women (%), 2011
  • Figure 9: Pricing and Reimbursement in Oncology, Total Per-capita Expenditure on Pharmaceuticals, Top Five Countries of Europe and the US, $PPP, 1990-2010
  • Figure 10: Pricing and Reimbursement in Oncology, Public Pharmaceutical Expenditure, Pharmacies, Growth Rates (%), 2010-2012
  • Figure 11: Pricing and Reimbursement in Oncology, Germany, Healthcare Expenditure by Financing Agent, $ per inhabitant, 2007, 2008, 2009
  • Figure 12: Pricing and Reimbursement in Oncology, Germany, Structural Reforms by AMNOG, 2011
  • Figure 13: Pricing and Reimbursement in Oncology, European Counties, the US and Japan, Total Healthcare Expenditure vs. Out-of-Pocket Expenditure, 2011
  • Figure 14: Pricing and Reimbursement in Oncology, Regulatory Bodies and Functions, France
  • Figure 15: Pricing and Reimbursement in Oncology, HTA to P&R Decisions, France
  • Figure 16: Pricing and Reimbursement in Oncology, Public and Private Expenditure on Health as % of Total Expenditure on Health, 2011
  • Figure 17: Pricing and Reimbursement in Oncology, Life Expectancy at Birth, Males and Females, Japan, 2011
Back to Top